Pharmaceutical Impurities
Products Related to Pharmaceutical Impurities(35)
- GC49683N-desethyl-N-methyl VardenafilCAS: 224785-87-9Purity: >95.00%
A potential impurity found in commercial preparations of vardenafil
- GC49690(3R,5R)-Rosuvastatin (calcium salt)CAS: 1422515-55-6Purity: >95.00%
A potential impurity found in bulk preparations of rosuvastatin
- GC62026Devaleryl Valsartan ImpurityCAS: 676129-92-3Purity: >99.50%
Devaleryl Valsartan Impurity is an intermediate in the synthesis of Valsartan.
- GC90480Safinamide Metabolite NW 1689CAS: 405-85-6Purity: >95.00%
A potential impurity found in commercial preparations of safinamide
- GC905172,2'-BisnaloxoneCAS: 211738-08-8Purity: >95.00%
A potential impurity in commercial preparations of naloxone
- GC91212SM-102 N-oxideCAS: 2824195-50-6Purity: >98.00%
A potential impurity in commercial preparations of SM-102
- GC913655-(4'-(Azidomethyl)(1,1'-biphenyl)-2-yl)-2H-tetrazoleCAS: 152708-24-2Purity: >95.00%
5-(4'-(Azidomethyl)(1,1'-biphenyl)-2-yl)-2H-tetrazole (AZTT) is a potential impurity found in commercial preparations of tetrazole-containing sartans, including losartan, irbesartan, and valsartan.
- GC91450De-Boc-CabazitaxelCAS: 1638286-64-2Purity: >95.00%
De-Boc-Cabazitaxel is a potential impurity in commercial preparations of the semisynthetic taxane cabazitaxel.
- GC91453ALC-0315 N-oxidePurity: >98.00%
ALC-0315 N-oxide is a potential impurity in commercial preparations of the ionizable cationic amino lipid ALC-0315.
- GC91548Rosuvastatin EP Impurity A (calcium salt)CAS: 1714147-47-3Purity: >98.00%
Rosuvastatin EP impurity A is a potential impurity in commercial preparations of the HMG-CoA reductase inhibitor rosuvastatin.
- GC91669m-isobutyl IbuprofenCAS: 66622-47-7Purity: >98.00%
m-isobutyl Ibuprofen is a potential impurity in commercial preparations of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor ibuprofen.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC49683 | N-desethyl-N-methyl Vardenafil | 224785-87-9 | >95.00% | |
A potential impurity found in commercial preparations of vardenafil | ||||
| GC49690 | (3R,5R)-Rosuvastatin (calcium salt) | 1422515-55-6 | >95.00% | |
A potential impurity found in bulk preparations of rosuvastatin | ||||
| GC62026 | Devaleryl Valsartan Impurity | 676129-92-3 | >99.50% | |
Devaleryl Valsartan Impurity is an intermediate in the synthesis of Valsartan. | ||||
| GC90480 | Safinamide Metabolite NW 1689 | 405-85-6 | >95.00% | |
A potential impurity found in commercial preparations of safinamide | ||||
| GC90517 | 2,2'-Bisnaloxone | 211738-08-8 | >95.00% | |
A potential impurity in commercial preparations of naloxone | ||||
| GC91212 | SM-102 N-oxide | 2824195-50-6 | >98.00% | |
A potential impurity in commercial preparations of SM-102 | ||||
| GC91365 | 5-(4'-(Azidomethyl)(1,1'-biphenyl)-2-yl)-2H-tetrazole | 152708-24-2 | >95.00% | |
5-(4'-(Azidomethyl)(1,1'-biphenyl)-2-yl)-2H-tetrazole (AZTT) is a potential impurity found in commercial preparations of tetrazole-containing sartans, including losartan, irbesartan, and valsartan. | ||||
| GC91450 | De-Boc-Cabazitaxel | 1638286-64-2 | >95.00% | |
De-Boc-Cabazitaxel is a potential impurity in commercial preparations of the semisynthetic taxane cabazitaxel. | ||||
| GC91453 | ALC-0315 N-oxide | - | >98.00% | |
ALC-0315 N-oxide is a potential impurity in commercial preparations of the ionizable cationic amino lipid ALC-0315. | ||||
| GC91548 | Rosuvastatin EP Impurity A (calcium salt) | 1714147-47-3 | >98.00% | |
Rosuvastatin EP impurity A is a potential impurity in commercial preparations of the HMG-CoA reductase inhibitor rosuvastatin. | ||||
| GC91669 | m-isobutyl Ibuprofen | 66622-47-7 | >98.00% | |
m-isobutyl Ibuprofen is a potential impurity in commercial preparations of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor ibuprofen. | ||||